Effect of single versus multiple prophylactic antibiotic doses on prosthetic joint infections following primary total hip arthroplasty in patients with osteoarthritis at public and private hospitals in Denmark: protocol for a nationwide cross-over, cluster randomised, non-inferiority trial [The Pro-Hip-Quality Trial]
Authors:
- Armita Armina AbediAAArmita Armina Abedi
- Claus VarnumCVClaus Varnum
- Alma Becic PedersenAPAlma Becic Pedersen
- Kirill GromovKGKirill Gromov
- Jesper HallasJHJesper Hallas
- Espen Jimenez-SolemEJEspen Jimenez-Solem
- Kristian KidholmKKKristian Kidholm
- Anne KjerulfAKAnne Kjerulf
- Jeppe LangeJLJeppe Lange
- Anders OdgaardAOAnders Odgaard
Open Access
Abstract
Introduction A feared complication after total hip arthroplasty (THA) is prosthetic joint infection (PJI), associated with high morbidity and mortality. Prophylactic antibiotics can reduce the risk of PJI. However, there is no consensus on the dosages and current recommendations are based on a low evidence level. The objective is to compare the effect of a single versus multiple doses of prophylactic antibiotics administered within 24 hours on PJI. Methods and analysis The study is designed as a cross-over, cluster randomised, non-inferiority trial. All clinical centres use both antibiotic practices (1 year of each intervention). All Danish orthopaedic surgery departments will be involved: Based on quality databases, 2-year cohorts of approximately 20 000 primary THAs conducted at 39 public and private hospitals, will be included. Inclusion criteria: age ≥18 years, all indications for THA except patients operated due to acute or sequelae from proximal femoral or pelvic fractures or bone tumour or metastasis. The primary outcome is PJI within 90 days after primary THA. Secondary outcomes include (1) serious adverse events, (2) potential PJI, (3) length of hospitalisation stay, (4) cardiovascular events, (5) hospital-treated infections, (6) community-based antibiotic use, (7) opioid use and (8) use of acetaminophen and non-steroidal anti-inflammatory drugs. All outcome measures will be extracted from national databases. Analyses will be based on the intention-to-treat population. Non-inferiority will be shown if the upper limit of the two-sided 95% CI for the OR is less than 1.32 for the single dose as compared with multiple doses. The results will establish best practice on antibiotic prophylaxis dosages in the future. Ethics and dissemination This study has been approved by Committees on Health Research Ethics for The Capital Region of Denmark (21069108) and The Danish Medicines Agency (2021091723). All results will be presented in peer-reviewed medical journals and international conferences. Trial registration number NCT05530551.Keywords
Funding Information
- Novo Nordic Foundation (N/A)
- The Danish Rheumatism Association ((R201-A7259))
- Medicine Fund of the Danish Regions (N/A)
- Oak Foundation (OCAY-18-774-OFIL)
This publication has 56 references indexed in Scilit:
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- Consort 2010 statement: extension to cluster randomised trialsBMJ, 2012
- Danish registers on personal income and transfer paymentsScandinavian Journal of Public Health, 2011
- Danish education registersScandinavian Journal of Public Health, 2011
- The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of PatientsBMC Medical Research Methodology, 2011
- Medical complications in patients with stroke: data validity in a stroke registry and a hospital discharge registryClinical Epidemiology, 2010
- Improving the reporting of pragmatic trials: an extension of the CONSORT statementBMJ, 2008
- Antibiotic Prophylaxis and the Risk of Surgical Site Infections following Total Hip Arthroplasty: Timely Administration Is the Most Important FactorClinical Infectious Diseases, 2007
- LONG-TERM RESULTS OF PROPHYLACTIC CEFAZOLIN VERSUS PLACEBO IN TOTAL HIP REPLACEMENTThe Lancet, 1987
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987